Eletriptan Hydrobromide Tablet, Film Coated
FDA Label NDC 0093-8310

35 label sections · Submitted to the FDA by Teva Pharmaceuticals Usa, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Pharmaceuticals Usa, Inc. for the product Eletriptan Hydrobromide (NDC 0093-8310). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2 dosage and administration, 3 dosage forms and strengths, 4 contraindications, 5 warnings and precautions, 5.1 myocardial ischemia, myocardial infarction, and prinzmetal’s angina, 5.2 arrhythmias, 5.3 chest, throat, neck and/or jaw pain/tightness/pressure, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.